HomeCompareALPMF vs SBUX

ALPMF vs SBUX: Dividend Comparison 2026

ALPMF yields 3.14% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALPMF wins by $25.83M in total portfolio value
10 years
ALPMF
ALPMF
● Live price
3.14%
Share price
$16.15
Annual div
$0.51
5Y div CAGR
83.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.00M
Annual income
$22,649,486.27
Full ALPMF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — ALPMF vs SBUX

📍 ALPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPMFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPMF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPMF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPMF
Annual income on $10K today (after 15% tax)
$267.05/yr
After 10yr DRIP, annual income (after tax)
$19,252,063.33/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, ALPMF beats the other by $19,191,597.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPMF + SBUX for your $10,000?

ALPMF: 50%SBUX: 50%
100% SBUX50/50100% ALPMF
Portfolio after 10yr
$13.08M
Annual income
$11,360,311.36/yr
Blended yield
86.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

ALPMF
No analyst data
Altman Z
2.8
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPMF buys
0
SBUX buys
0
No recent congressional trades found for ALPMF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPMFSBUX
Forward yield3.14%2.84%
Annual dividend / share$0.51$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83.1%48.3%
Portfolio after 10y$26.00M$167.0K
Annual income after 10y$22,649,486.27$71,136.45
Total dividends collected$25.70M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: ALPMF vs SBUX ($10,000, DRIP)

YearALPMF PortfolioALPMF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,275$575.25$11,121$420.68+$154.00ALPMF
2$13,174$1,109.91$12,548$648.40+$626.00ALPMF
3$16,316$2,219.21$14,440$1,013.98+$1.9KALPMF
4$22,161$4,703.07$17,068$1,617.30+$5.1KALPMF
5$34,643$10,931.15$20,912$2,649.52+$13.7KALPMF
6$66,310$29,241.64$26,875$4,499.29+$39.4KALPMF
7$166,730$95,777.84$36,771$8,014.12+$130.0KALPMF
8$590,501$412,100.01$54,542$15,197.11+$536.0KALPMF
9$3,129,389$2,497,553.06$89,602$31,242.49+$3.04MALPMF
10$25,997,932$22,649,486.27$167,011$71,136.45+$25.83MALPMF

ALPMF vs SBUX: Complete Analysis 2026

ALPMFStock

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Full ALPMF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this ALPMF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPMF vs SCHDALPMF vs JEPIALPMF vs OALPMF vs KOALPMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.